These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 9305508)

  • 21. Behavioral outcomes in clinical trials for Alzheimer disease.
    Ferris SH; Mackell JA
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 4():S10-5. PubMed ID: 9339267
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmacological treatment in severe dementia].
    Jouanny P; Belliard S; Bentué-Ferrer D; Michel O; Allain H
    Psychol Neuropsychiatr Vieil; 2005 Mar; 3 Suppl 1():S51-5. PubMed ID: 15899605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuropsychiatric outcome for clinical trials.
    Robert P; Verhey FR; Aalten P; Cortes F; Byrne EJ
    J Nutr Health Aging; 2007; 11(4):345-7. PubMed ID: 17653496
    [No Abstract]   [Full Text] [Related]  

  • 24. The need for a consensus in the use of assessment tools for Alzheimer's disease: the Feasibility Study (assessment tools for dementia in Alzheimer Centres across Europe), a European Alzheimer's Disease Consortium's (EADC) survey.
    Paulino Ramirez Diaz S; Gil Gregório P; Manuel Ribera Casado J; Reynish E; Jean Ousset P; Vellas B; Salmon E
    Int J Geriatr Psychiatry; 2005 Aug; 20(8):744-8. PubMed ID: 16035121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes for clinical trials in mild-to-moderate dementia to evaluate drugs with presumably symptomatic effects.
    Frolich L
    J Nutr Health Aging; 2007; 11(4):357-8. PubMed ID: 17653499
    [No Abstract]   [Full Text] [Related]  

  • 26. Measuring cognitive change in Alzheimer's disease clinical drug trials.
    Harrison JE
    J Nutr Health Aging; 2007; 11(4):327-9. PubMed ID: 17653492
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recommendations for best practices in the treatment of Alzheimer's disease in managed care.
    Fillit HM; Doody RS; Binaso K; Crooks GM; Ferris SH; Farlow MR; Leifer B; Mills C; Minkoff N; Orland B; Reichman WE; Salloway S
    Am J Geriatr Pharmacother; 2006; 4 Suppl A():S9-S24; quiz S25-S28. PubMed ID: 17157793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cholinesterase inhibitors in the treatment of Alzheimer's disease and related dementias.
    Masterman D
    Clin Geriatr Med; 2004 Feb; 20(1):59-68. PubMed ID: 15062487
    [No Abstract]   [Full Text] [Related]  

  • 29. Reflections on the assessment of behavior in nursing home residents.
    Cohen-Mansfield J
    Alzheimer Dis Assoc Disord; 1994; 8 Suppl 1():S217-22. PubMed ID: 8068263
    [No Abstract]   [Full Text] [Related]  

  • 30. Comments on measurement of severe dementia.
    Zandi T
    Alzheimer Dis Assoc Disord; 1994; 8 Suppl 1():S206-8. PubMed ID: 8068260
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment of impaired cognition with nootropic drugs: nicergoline versus the state of the art.
    Fariello RG
    Funct Neurol; 1997; 12(3-4):221-5. PubMed ID: 9218984
    [No Abstract]   [Full Text] [Related]  

  • 32. Measurement issues in chronic care populations: dementia special care.
    Teresi J; Lawton MP; Ory M; Holmes D
    Alzheimer Dis Assoc Disord; 1994; 8 Suppl 1():S144-83. PubMed ID: 8068256
    [No Abstract]   [Full Text] [Related]  

  • 33. Dementia staging in chronic care populations.
    Reisberg B; Sclan SG; Franssen E; Kluger A; Ferris S
    Alzheimer Dis Assoc Disord; 1994; 8 Suppl 1():S188-205. PubMed ID: 8068258
    [No Abstract]   [Full Text] [Related]  

  • 34. Reliability and clinical concepts underlying global judgments in dementia: implications for clinical research.
    Dahlke F; Lohaus A; Gutzmann H
    Psychopharmacol Bull; 1992; 28(4):425-32. PubMed ID: 1296220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical trials in Alzheimer disease. Comments on the project of FDA's guidelines].
    Spriet A; Dupin-Spriet T
    Therapie; 1993; 48(3):211-3. PubMed ID: 8140560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alzheimer disease-related activities in China: a report from the International Working Group on the Harmonization of Dementia Drug Guidelines.
    Doody R; Whitehouse PJ; Chen Q; Wang L; Wu Q; Rosser M; Xu XH
    Alzheimer Dis Assoc Disord; 1998 Dec; 12(4):263-5. PubMed ID: 9876954
    [No Abstract]   [Full Text] [Related]  

  • 37. ADCS Prevention Instrument Project: ADCS-clinicians' global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versions.
    Schneider LS; Clark CM; Doody R; Ferris SH; Morris JC; Raman R; Reisberg B; Schmitt FA
    Alzheimer Dis Assoc Disord; 2006; 20(4 Suppl 3):S124-38. PubMed ID: 17135806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Nootropic drugs: definition, classification, mechanism of action, clinical effectiveness, substances].
    Kuhlmey J
    Z Arztl Fortbild (Jena); 1994 Sep; 88(9):697-701. PubMed ID: 7975756
    [No Abstract]   [Full Text] [Related]  

  • 39. Assessing outcomes in Alzheimer disease.
    Schneider LS
    Alzheimer Dis Assoc Disord; 2001 Aug; 15 Suppl 1():S8-18. PubMed ID: 11669509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Review of outcome measurement instruments in Alzheimer's disease drug trials: psychometric properties of functional and quality of life scales.
    Demers L; Oremus M; Perrault A; Champoux N; Wolfson C
    J Geriatr Psychiatry Neurol; 2000; 13(4):170-80. PubMed ID: 11128057
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.